Enhancement of pharmacokinetic and pharmacological behavior of ocular dorzolamide after factorial optimization of self-assembled nanostructures
- PMID: 29401498
- PMCID: PMC5798776
- DOI: 10.1371/journal.pone.0191415
Enhancement of pharmacokinetic and pharmacological behavior of ocular dorzolamide after factorial optimization of self-assembled nanostructures
Abstract
Dorzolamide hydrochloride is frequently administered for the control of the intra-ocular pressure associated with glaucoma. The aim of this study is to develop and optimize self-assembled nanostructures of dorzolamide hydrochloride and L-α-Phosphatidylcholine to improve the pharmacokinetic parameters and extend the drug pharmacological action. Self-assembled nanostructures were prepared using a modified thin-film hydration technique. The formulae compositions were designed based on response surface statistical design. The prepared self-assembled nanostructures were characterized by testing their drug content, particle size, polydispersity index, zeta potential, partition coefficient, release half-life and extent. The optimized formulae having the highest drug content, zeta potential, partition coefficient, release half-life and extent with the lowest particle size and polydispersity index were subjected to further investigations including investigation of their physicochemical, morphological characteristics, in vivo pharmacokinetic and pharmacodynamic profiles. The optimized formulae were prepared at pH 8.7 (F5 and F6) and composed of L-α-Phosphatidylcholine and drug mixed in a ratio of 1:1 and 2:1 w/w, respectively. They showed significantly higher Cmax, [Formula: see text] and [Formula: see text] at the aqueous humor with extended control over the intra-ocular pressure, when compared to the marketed product; Trusopt®. The study introduced novel and promising self-assembled formulae able to permeate higher drug amount through the cornea and achieve sustained pharmacological effect at the site of action.
Conflict of interest statement
Figures





Similar articles
-
Cubogel as potential platform for glaucoma management.Drug Deliv. 2021 Dec;28(1):293-305. doi: 10.1080/10717544.2021.1872740. Drug Deliv. 2021. PMID: 33509004 Free PMC article.
-
Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits.Drug Deliv. 2018 Nov;25(1):1340-1349. doi: 10.1080/10717544.2018.1477861. Drug Deliv. 2018. PMID: 29869516 Free PMC article.
-
Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation.Int J Pharm. 2019 Oct 30;570:118662. doi: 10.1016/j.ijpharm.2019.118662. Epub 2019 Sep 3. Int J Pharm. 2019. PMID: 31491481
-
Topical drug delivery to the eye: dorzolamide.Acta Ophthalmol. 2012 Nov;90(7):603-8. doi: 10.1111/j.1755-3768.2011.02299.x. Epub 2012 Jan 23. Acta Ophthalmol. 2012. PMID: 22269010 Review.
-
Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.Drugs Aging. 1997 May;10(5):384-403. doi: 10.2165/00002512-199710050-00006. Drugs Aging. 1997. PMID: 9143858 Review.
Cited by
-
Advancements and Prospects in Nanorobotic Applications for Ophthalmic Therapy.ACS Biomater Sci Eng. 2025 Feb 10;11(2):958-980. doi: 10.1021/acsbiomaterials.4c02368. Epub 2025 Jan 17. ACS Biomater Sci Eng. 2025. PMID: 39818739 Free PMC article. Review.
-
Advances in dorzolamide hydrochloride delivery: harnessing nanotechnology for enhanced ocular drug delivery in glaucoma management.Discov Nano. 2024 Dec 10;19(1):199. doi: 10.1186/s11671-024-04154-x. Discov Nano. 2024. PMID: 39656411 Free PMC article. Review.
-
An Update on Novel Drug Delivery Systems for the Management of Glaucoma.Pharmaceutics. 2025 Aug 21;17(8):1087. doi: 10.3390/pharmaceutics17081087. Pharmaceutics. 2025. PMID: 40871105 Free PMC article. Review.
-
Cubogel as potential platform for glaucoma management.Drug Deliv. 2021 Dec;28(1):293-305. doi: 10.1080/10717544.2021.1872740. Drug Deliv. 2021. PMID: 33509004 Free PMC article.
-
Breaking Barriers in Eye Treatment: Polymeric Nano-Based Drug-Delivery System for Anterior Segment Diseases and Glaucoma.Polymers (Basel). 2023 Mar 9;15(6):1373. doi: 10.3390/polym15061373. Polymers (Basel). 2023. PMID: 36987154 Free PMC article. Review.
References
-
- Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis Ophthalmology. 2014;121: 2081–2090. doi: 10.1016/j.ophtha.2014.05.013 - DOI - PubMed
-
- Stone JS, Muir KW, Stinnett SS, Rosdahl JA. Glaucoma blindness at a tertiary eye care center. North Carolina medical journal. 2015;76: 211–218. doi: 10.18043/ncm.76.4.211 - DOI - PMC - PubMed
-
- Lewis RA, Christie WC, Day DG, Craven ER, Walters T, Bejanian M, et al. Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial. American journal of ophthalmology. 2017; 175: 137–147. doi: 10.1016/j.ajo.2016.11.020 - DOI - PubMed
-
- Scozzafava A, Supuran CT.Glaucoma and the applications of carbonic anhydrase inhibitors, Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications. Springer, 2014; pp. 349–359. - PubMed
-
- Hasan AA.Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride. Pharmaceutical development and technology. 2014; 19: 748–754. doi: 10.3109/10837450.2013.829095 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous